Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Research Investment’s Graeme Martin on Corporate Venture Capital’s New Role In Developing Next-Generation Biologics: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

Attend any industry conference these days, and a general theme will appear that venture capital is not as readily available as it once was. A dearth of venture funding, particularly for early-stage research, could impact long-term future development of emerging biotechnologies. Graeme Martin, president of Takeda's corporate venture arm Takeda Research Investment, talks with PharmAsia News about the changing scope of corporate venture capital in this atmosphere as well as the role of CVC in helping inform companies' development strategies.

You may also be interested in...



At PharmAsia Summit, VCs Discuss Financing Innovation in Asia

As returns falter in the U.S., VC firms are finding that infrastructure investments overseas are opening up uncharted territory for the life sciences industry.

At PharmAsia Summit, VCs Discuss Financing Innovation in Asia

As returns falter in the U.S., VC firms are finding that infrastructure investments overseas are opening up uncharted territory for the life sciences industry.

Takeda Research Investment’s Graeme Martin On Corporate Venture Capital’s Role in Developing Next-Generation Biologics: An Interview With PharmAsia News(Part 2 of 2)

Attend any industry conference these days, and a general theme arises that venture capital is not as readily available as it once was. A dearth of venture funding, particularly for early-stage projects, could impact long-term future development of emerging biotechnologies.

UsernamePublicRestriction

Register

SC010771

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel